RADIOLOGY

DIAL 452-9319

RADIOLOGY ASSOCIATES, INC.
PAUL A. JONES, M.D.
JOSEPH S. SAFKO, M.D.
DALE R. BOYSE, M.D.
JOHN W. STEINBERGER, M.D.
DAVID NEELAND, M.D.
838 MARKET STREET
P.O. BOX 231
ZANESVILLE, OHIO 43701

June 17, 1985

Mr. James Mullauer
Materials Licensing Section
U. S. Nuclear Regulatory Commission
Region III
799 Roosevelt Road
Glen Ellyn, IL 60137

Re: By-Product Material License No. 34-13165-01

Control No. 77843

Dear Mr. Mullauer:

We have received your letter of June 4, 1985 regarding our application for license renewal.

1. THERAPEUTIC LIQUID IODINE-131:
We are not using liquid therapeutic iodine-131 at the present time. Calibrated capsules are being used instead. We have had no evidence of volatile iodine being released when the cap is removed from the container containing the capsule.

2. BIOASSAY PROGRAM:
A bioassay program is not indicated when using only capsules. At any time when a capsule might be damaged or a patient would vomit after receiving a capsule, we measure the possible thyroid uptake in the technologist or personnel in the area for a minimum of 24 hours to determine whether they have received significant uptake.

3. PATIENT DOSES:
We receive our dose capsules from an approved radiopharmaceutical supplier. These are all precalibrated by them. We have spot checked the capsules to assure ourselves the supplier is accurate and careful in their assay, and have no reason to doubt them at this time. We feel it is not necessary to assay every capsule.

Any patient doses which vary by more than 10% from the prescribed dose are not administered to the patient.

4. AREA SURVEYS:
Area surveys are performed when capsules are received or stored, and following administration. The storage, dose preparation, and administration areas are all monitored to assure that no leakage has occurred.

I hope this answers your questions. If not, we will be glad to discuss them.

Sincerely,

Joseph S. Safko, M. D.

JSS:mt